TY - JOUR
T1 - Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs
AU - Zhang, Yanfang
AU - Gao, Liangcai
AU - Yao, Bingyi
AU - Huang, Shengbo
AU - Zhang, Yuanjin
AU - Liu, Jie
AU - Liu, Zongjun
AU - Wang, Xin
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Epoxyeicosatrienoic acids (EETs) are important endogenous substances that affect heart function in human body. Animal models of cytochrome P450 (CYP) and soluble epoxide hydrolase (sEH) related cardiovascular diseases (CVD) have revealed the physiological effects of EETs, mainly including vascular function regulation, angiogenesis, myocardial fibrosis, myocardial hypertrophy, and cardiovascular inflammation. At the same time, clinical studies have found that most of the substrates and inhibitors of CYP2J2 affect the content of EETs, resulting in cardiotoxicity of drugs. Therefore, the regulation of CYP and sEH enzymes on EETs points out the direction for exploring EET-mediated cardiac protection. The metabolic pathway of EETs is not only an important target for the development of new drugs for CVD but also an important factor in preventing drug cardiotoxicity. The development and clinical application of sEH inhibitors and EETs analogues provide broad prospects for the treatment of CVD.
AB - Epoxyeicosatrienoic acids (EETs) are important endogenous substances that affect heart function in human body. Animal models of cytochrome P450 (CYP) and soluble epoxide hydrolase (sEH) related cardiovascular diseases (CVD) have revealed the physiological effects of EETs, mainly including vascular function regulation, angiogenesis, myocardial fibrosis, myocardial hypertrophy, and cardiovascular inflammation. At the same time, clinical studies have found that most of the substrates and inhibitors of CYP2J2 affect the content of EETs, resulting in cardiotoxicity of drugs. Therefore, the regulation of CYP and sEH enzymes on EETs points out the direction for exploring EET-mediated cardiac protection. The metabolic pathway of EETs is not only an important target for the development of new drugs for CVD but also an important factor in preventing drug cardiotoxicity. The development and clinical application of sEH inhibitors and EETs analogues provide broad prospects for the treatment of CVD.
KW - Cardiotoxicity
KW - Cardiovascular diseases (CVD)
KW - Cytochrome P450 2J (CYP2J)
KW - Epoxyeicosatrienoic acids (EETs)
KW - Soluble epoxide hydrolase (sEH)
UR - https://www.scopus.com/pages/publications/85140575048
U2 - 10.1016/j.lfs.2022.121122
DO - 10.1016/j.lfs.2022.121122
M3 - 文献综述
C2 - 36309225
AN - SCOPUS:85140575048
SN - 0024-3205
VL - 310
JO - Life Sciences
JF - Life Sciences
M1 - 121122
ER -
